A Comprehensive, Customizable Life Sciences Commercialization Model
Even though pharma companies spend more than $125 million over the three years leading up to a drug’s launch, 66% of launches don’t meet expectations. Financial risk, industry pressures and unforeseen complexities are forcing developers and investors to seek advanced commercialization options that maximize their pipelines.
EVERSANA COMPLETE Commercialization®, an award-winning model that is disrupting the pharma industry, offers an alternative to selling, out-licensing or launching internally.